Sonoma Pharmaceuticals
SNOA
18 hedge funds and large institutions have $825K invested in Sonoma Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 8 closing their positions.
0.03% more ownership
Funds ownership: 0.07% → 0.1% (+0.03%)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
22% less funds holding
Funds holding: 23 → 18 (-5)
28% less capital invested
Capital invested by funds: $1.15M → $825K (-$320K)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$515K |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$89.6K |
| 3 |
Renaissance Technologies
New York
|
+$71.2K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$12.8K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$10.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
Bard Associates
Chicago,
Illinois
|
-$88.6K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$66K |
| 3 |
JAM
JW Asset Management
Miami Beach,
Florida
|
-$60K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$41.7K |
| 5 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$22K |
SNOA Hedge Fund Activity: Q4 2018 in Review
18 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q4 2018, worth a combined $825K — down 28% from $1.15M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of SNOA and 3 opened new positions — a net loss of 5 holders — while 5 trimmed existing stakes and 4 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $515K. The largest seller was Bard Associates, cutting an estimated $88.6K.
- 18 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q4 2018, down from 23 in Q3 2018.
- Funds reported $825K of Sonoma Pharmaceuticals stock for Q4 2018, down 28% quarter-over-quarter.
- 3 funds opened new Sonoma Pharmaceuticals positions in Q4 2018 and 8 closed out, a net change of -5 holders.
- The largest Sonoma Pharmaceuticals buyer in Q4 2018 was Sabby Management, an estimated $515K added.
- The largest Sonoma Pharmaceuticals seller in Q4 2018 was Bard Associates, an estimated $88.6K sold.
Based on aggregated 13F filings for Q4 2018.